罕见遗传变异在个体化药物治疗中的考量
个体化药物治疗需综合考虑遗传、病理生理、饮食、环境及合并用药等因素。近几十年已发现大量患者遗传构成与药物药代动力学和药效学的关联,主要涉及药物代谢酶和转运体基因的常见单核苷酸变异与拷贝数变异,以及主要组织相容性复合体变异对免疫介导药物毒性的预测。FDA和EMA已认可超过230个药物基因组生物标志物并纳入药品说明书,在癌症治疗中尤其有助于避免不良反应和疗效不佳。
要点
- 药物基因组生物标志物已超230个获FDA和EMA认可并纳入药品说明书。
- 常见SNV和CNV主要影响ADME基因功能,MHC变异可预测免疫介导药物毒性。
- 在癌症治疗中,药物基因组标志物有助于避免不良反应和疗效不佳。
核心结论
- 个体化药物治疗应综合考虑遗传、病理生理、饮食、环境及合并用药等因素以优化疗效。
- 药物基因组生物标志物可一定程度预测药物疗效或不良反应可能性,已获监管机构认可并纳入药品说明书。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 已发现大量患者遗传构成与药物药代动力学和药效学的关联,主要涉及药物代谢酶和转运体基因的常见单核苷酸变异和拷贝数变异。
- 主要组织相容性复合体区域的遗传变异有助于预测免疫介导的药物毒性。
- 超过230个药物基因组生物标志物获FDA和EMA认可并纳入相应药品说明书。
- 这些标志物在癌症治疗中尤其有助于避免不良反应和疗效不佳。
临床怎么用
- 临床可参考FDA和EMA认可并纳入药品说明书的药物基因组生物标志物,辅助预测药物疗效或不良反应风险。
- 在癌症治疗中可利用药物基因组信息帮助避免不良反应和疗效不佳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Personalized drug therapy aims to optimize the efficacy of pharmacological treatments by considering genetic, pathophysiological, dietary, and environmental factors as well as comedications and compliance. A multitude of associations between the specific genetic constitution of the patient and drug pharmacokinetics and pharmacodynamics has been identified in the last decades that encompass mainly common single nucleotide variants (SNVs) and gene copy number variations (CNVs) of importance for the function of genes encoding drug-metabolizing enzymes and transporters involved in drug absorption, distribution, metabolism, and excretion (ADME). In addition, genetic variation in factors encoding the major histocompatibility complex have been helpful to predict immune-mediated drug toxicity. This knowledge has been translated into clinical applications through the implementation of pharmacogenomic biomarkers. Over 230 of such markers that can, to a certain extent, predict drug efficacy or the likelihood of adverse drug reactions (ADRs) are recognized by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and are included in the drug labels of the respective medication. They are of particular value in cancer therapy to provide information of use to avoid ADRs and lack of response.
引用
- Lauschke VM, Ingelman-Sundberg M. How to Consider Rare Genetic Variants in Personalized Drug Therapy. Clin Pharmacol Ther. 2018. PMID: 29313952. doi:10.1002/cpt.976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。